Myeloid effector cells in cancer

Authors: Schol, Pieter ^{1, 2}, van Elsas, Marit J. ^{1, 2}, Middelburg, Jim ^{1, 2}, Nijen Twilhaar, Maarten K. ¹, van Hall, Thorbald ¹, van der Sluis, Tetje C. ¹, van der Burg, Sjoerd H. ^{1, ∗}

Source: In Cancer Cell 9 December 2024 42(12):1997-2014

Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy

Authors: van Elsas, Marit J., Middelburg, Jim, Labrie, Camilla, Roelands, Jessica, Schaap, Gaby, Sluijter, Marjolein, Tonea, Ruxandra, Ovcinnikovs, Vitalijs, Lloyd, Katy, Schuurman, Janine, Riesenfeld, Samantha J., Gajewski, Thomas F., de Miranda, Noel F.C.C., van Hall, Thorbald, van der Burg, Sjoerd H.

Source: In Cancer Cell 10 June 2024 42(6):1032-1050

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.

Authors: van Elsas, Marit J.¹ (AUTHOR), van der Schoot, Johan M. S.² (AUTHOR), Bartels, Alexander² (AUTHOR), Steuten, Kas² (AUTHOR), van Dalen, Duco^2,3 (AUTHOR), Wijfjes, Zacharias^2,3 (AUTHOR), Figdor, Carl G.² (AUTHOR), van Hall, Thorbald¹ (AUTHOR), van der Burg, Sjoerd H.¹ (AUTHOR), Verdoes, Martijn^2,3 (AUTHOR) martijn.verdoes@radboudumc.nl, Scheeren, Ferenc A.⁴ (AUTHOR) martijn.verdoes@radboudumc.nl

Source: International Journal of Molecular Sciences. Aug2022, Vol. 23 Issue 15, p8707-8707. 13p.

Subject Terms: *REGULATORY T cells, *CD25 antigen, *IMMUNE response, *RECOMBINANT antibodies, *CRISPRS, *T cells, *CYTOTOXIC T cells

NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division.

Authors: Borst, Linda, Sluijter, Marjolein, Sturm, Gregor, Charoentong, Pornpimol, Santegoets, Saskia J., van Gulijk, Mandy, van Elsas, Marit J., Groeneveldt, Christianne, van Montfoort, Nadine, Finotello, Francesca, Trajanoski, Zlatko, Kiełbasa, Szymon M., van der Burg, Sjoerd H., van Hall, Thorbald

Source: International Journal of Cancer; Feb2022, Vol. 150 Issue 4, p688-704, 17p

Subject Terms: IMMUNE checkpoint proteins, CD8 antigen, T cells, CELL division, TH2 cells, ANTIGEN presenting cells, KILLER cells

Future Challenges in Cancer Resistance to Immunotherapy.

Authors: van Elsas, Marit J.¹ (AUTHOR) m.j.van_elsas@lumc.nl, van Hall, Thorbald¹ (AUTHOR), van der Burg, Sjoerd H.¹ (AUTHOR) shvdburg@lumc.nl

Source: Cancers. Apr2020, Vol. 12 Issue 4, p935-935. 1p.

Subject Terms: *ANTINEOPLASTIC agents, *DRUG resistance in cancer cells, *IMMUNOTHERAPY, *CANCER vaccines